ESMO Gastrointestinal Cancers Congress 2024
Ten years of improvement in the treatment of liver cancer
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Growing evidence supports the use of ctDNA as a biomarker in colon cancer
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Harnessing the power of the gut microbiome in colorectal cancer
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
Liver transplantation plus chemotherapy prolongs survival in patients with definitively unresectable colorectal liver metastases
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population
No significant survival benefits reported for perioperative chemoimmunotherapy in resectable G/GEJ cancers
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting
177Lu-DOTATATE shows efficacy in both grade 2 high and grade 3 low GEP-NETs
Promising data from a subgroup analysis of the phase III NETTER-2 study support the use of peptide receptor radionuclide therapy in treatment-naïve patients
Blood-based tests show promise in improving hepatocellular carcinoma management
Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection
Targeting KRAS offers new hope for patients with gastrointestinal cancers
The development of KRAS selective inhibitors promises to expand treatment to a broader population of patients with KRAS-mutated tumours
Why are gastrointestinal cancer patients getting younger?
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract